<DOC>
	<DOCNO>NCT01991483</DOCNO>
	<brief_summary>This study evaluate safety LY2928057 LY2928057 affect hemoglobin hemodialysis participant . This study involve multiple dos LY2928057 give 6 week period either participant discontinues reduces treatment stimulate red blood cell . This study last 26 week participant .</brief_summary>
	<brief_title>A Study LY2928057 Hemodialysis Participants</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Participants endstage renal disease ( ESRD ) , receive erythropoiesis stimulate agent ( ESA ) least weekly 2 week prior screen , receive adequate maintenance hemodialysis ( 3 time weekly ) least 12 week prior screen ( , approximate Kt/V great 1.1 ( K equal dialyzer clearance urea , equal dialysis duration time , V equal volume distribution urea , approximately equal participant 's total body water ) base clinical judgment participant 's nephrologist investigator willing stop ( Parts A B ) reduce ( Part C ) stable ESA dose week randomization completion 6week treatment period ( unless rescue therapy need ) Have hemoglobin value ( take prior dialysis take dialysis day ) great equal 9.5 gram per deciLiter ( g/dL ) less equal 12.5 g/dL screen Have body mass index ( BMI ) 18.5 45 kilogram per square meter ( kg/m^2 ) inclusive screen Have transferrin saturation ( TSat ) great equality 15 percent ferritin great 40 nanogram per milliliter ( ng/mL ) screen Any cause anemia renal disease A history hyporesponsiveness ESA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>